期刊
EXPERIMENTAL DERMATOLOGY
卷 31, 期 4, 页码 567-576出版社
WILEY
DOI: 10.1111/exd.14502
关键词
chimeric mice; histone deacetylase inhibitor; histone deacetylases; hyperproliferation; psoriasis; Vorinostat
类别
资金
- Kamin program [46303]
- Israel Science Foundation [840/09]
The study showed that the histone deacetylase inhibitor Vorinostat can effectively inhibit hyperproliferation of keratinocytes and induce their differentiation and apoptosis. In a chimeric mouse model, Vorinostat demonstrated significant improvement in psoriasis-like symptoms, indicating its potential use in treating psoriasis and other hyperproliferative skin disorders.
Background Psoriasis is characterized by aberrant activation of several pro-inflammatory circuits as well as abnormal hyperproliferation and dysregulated apoptosis of keratinocytes (KCs). Most currently available therapeutic options primarily target psoriasis-associated immunological defects rather than epidermal abnormalities. Objective To investigate the efficacy of the histone deacetylase (HDAC) inhibitor, Vorinostat, in targeting hyperproliferation and impaired apoptosis in psoriatic skin. Methods Vorinostat effect was investigated in primary KCs cell cultures using cell cycle analysis by flow cytometry, apoptosis assays (Annexin V-FICH and caspase-3/7) and antibody arrays, qRT-PCR and immunohistochemistry. Vorinostat impact on clinical manifestations of psoriasis was investigated in a chimeric mouse model. Results Vorinostat was found to inhibit KCs proliferation and to induce their differentiation and apoptosis. Using a chimeric mouse model, vorinostat was found to result in marked attenuation of a psoriasiform phenotype with a significant decrease in epidermal thickness and inhibition of epidermal proliferation. Conclusions Our results support the notion that vorinostat, a prototypic HDAC inhibitor, may be of potential use in the treatment of psoriasis and other hyperproliferative skin disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据